X
<

How US Pharmaceutical Companies Performed in 1Q17

PART:
1 2 3 4 5 6 7 8 9 10
Part 2
How US Pharmaceutical Companies Performed in 1Q17 PART 2 OF 10

How Pharmaceutical ETFs Performed during 1Q17

Pharmaceutical ETFs

Besides diversification, ETFs have other benefits, such as the ability to sell short, buy on margin, and purchase single units. Also, expense ratios for ETFs are much lower than they are for mutual funds.

How Pharmaceutical ETFs Performed during 1Q17

Interested in XLV? Don't miss the next report.

Receive e-mail alerts for new research on XLV

Success! You are now receiving e-mail alerts for new research. A temporary password for your new Market Realist account has been sent to your e-mail address.

Success! has been added to your Ticker Alerts.

Success! has been added to your Ticker Alerts. Subscriptions can be managed in your user profile.

The above chart compares pharmaceutical ETFs and their returns year-to-date (or YTD).

PowerShares Dynamic Pharmaceuticals ETF

The PowerShares Dynamic Pharmaceuticals ETF (PJP) is focused on both drug manufacturers and biotechnology companies. The fund has been operational since 2005, and its net assets were $761.6 million on March 31, 2017. Its holdings include pharmaceutical companies such as Eli Lilly and Company (LLY), Bristol-Myers Squibb (BMY), and Pfizer (PFE). It rose ~2.7% in 1Q17, while its YTD returns were 2.0% on April 7, 2017.

VanEck Vectors Pharmaceuticals ETF

The VanEck Vectors Pharmaceuticals ETF (PPH) is focused on large drug manufacturing companies, and its holdings include large companies such as Johnson & Johnson (JNJ), Novartis AG (NVS), and Pfizer. The fund has been operational since 2011, and its net assets were $333.1 million on March 31, 2017. It rose ~3.3% in 1Q17, while its YTD return was 2.9% on April 7, 2017.

Healthcare Select Sector SPDR ETF

The Healthcare Select Sector SPDR ETF (XLV) has been operational since 1998, and its net assets were $15.8 billion on March 31, 2017. This ETF is focused on pharmaceutical and biotechnology companies. It rose ~6.9% in 1Q17, and its YTD return was 6.7% on April 7, 2017.

iShares U.S. Pharmaceuticals ETF

The iShares U.S. Pharmaceuticals ETF (IHE) is focused on large drug manufacturers such as Pfizer, Merck & Co. (MRK), and Allergan (AGN). The fund has been operational since 2006, and its net assets were $717.1 million on March 31, 2017. Its price rose ~5.3% in 1Q17, and its YTD return was 4.9% on April 7, 2017.

SPDR S&P Pharmaceuticals ETF

The SPDR S&P Pharmaceuticals ETF (XPH) is focused on both drug manufacturers and biotechnology companies. The fund tracks an index that represents the pharmaceutical subindustry portion of the S&P Total Markets Index. The fund has been operational since 2006, and its net assets were $479.3 million on March 31, 2017. It rose ~4.4% in 1Q17, and its YTD return was 4.5% on April 7, 2017.

X

Please select a profession that best describes you: